Global PCOS Diagnostic Market Insights Forecasts to 2033

• The Global PCOS Diagnostic Market Size was Valued at USD 3.68 Billion in 2023
• The Market Size is Growing at a CAGR of 5.18% from 2023 to 2033
• The Worldwide PCOS Diagnostic Market Size is Expected to Reach USD 6.1 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global PCOS Diagnostic Market Size is Anticipated to Exceed USD 6.1 Billion by 2033, Growing at a CAGR of 5.18% from 2023 to 2033.

Market Overview

PCOS diagnostic refers to the procedure of detecting and evaluating polycystic ovary syndrome (PCOS), which is an illness in which there is an inequity in a woman’s hormones. Male sex hormones, or androgens, are normally produced in modest amounts by the adrenal glands and ovaries and aid in the healthy operation of the reproductive system. However, the adrenal glands, the ovaries, or both overproduce androgens in a woman with PCOS. Among other symptoms, this can result in excessive body and facial hair, acne, and obesity. To be diagnosed with PCOS, patients need to fulfill two requirements: irregular ovulation, which is frequently shown by an irregular menstrual cycle or the absence of a cycle, signs of raised androgen levels or a blood test positive patient has increased levels, multiple small cysts on the ovaries. To diagnose PCOS there are several tests, such as blood tests, pelvic ultrasounds, and pelvic exam. Even though there is no cure for PCOS, many medications are used to control the menstrual cycle and accomplish the condition’s symptoms. It is also caused by high levels of androgen, low-grade inflammation, ovarian cysts, excessive insulin, and hereditary anomalies. The expansion of the PCOS diagnostic market is mainly propelled by many key factors. The rising number of cases of PCOS contributes to the increasing demand for a precise and timely diagnosis of PCOS. Additionally, the rising awareness leads to enhanced detection and diagnosis of the syndrome. The invention of novel diagnostic tools and techniques plays an important role in propelling the market growth.

Report Coverage

This research report categorizes the market for the global PCOS diagnostic market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global PCOS diagnostic market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global PCOS diagnostic market.

Driving Factors

PCOS is a common hormonal syndrome, affecting a substantial number of women globally. The rising number of PCOS is one of the key drivers of the PCOS diagnostic market. Furthermore, there is an increasing awareness among healthcare workers and patients regarding PCOS and its possible health problems. Early diagnosis of PCOS is significant for the active management and prevention of related complications, including metabolic disorders, infertility, and cardiovascular disorders. This awareness boosts the demand for the PCOS diagnostic market. In addition, advancements in diagnostic technologies, like hormonal assays, ultrasound, and genetic testing, have enhanced the accuracy and effectiveness of PCOS diagnosis. These advancements permit healthcare workers to diagnose PCOS more efficiently and contribute to the expansion of the PCOS diagnostic market. Moreover, rising healthcare funding, especially in developing nations, supports the growth of the PCOS diagnostic market.

Restraining Factors

PCOS diagnosis is presently based on a grouping of clinical, biochemical, and imaging criteria. However, there is still constant discussion and an absence of consensus on certain diagnostic criteria. The absence of standardized diagnostic measures can lead to inconsistency in diagnosis and possibly hamper accurate evaluation and comparability of diagnostic results. In addition, costs associated with PCOS diagnostic procedures and testing can be a significant barrier, particularly in environments with limited resources. A few diagnosis techniques, like hormonal assays and imaging techniques, may need dedicated apparatus and expertise, which can drive up costs. Costs associated with PCOS diagnostic testing may be a deterrent for people searching for a prompt and reliable diagnosis, especially in areas with poor access to medical care.

Market Segmentation

The global PCOS diagnostic market share is classified into the type of diagnostic test and end user.

• The transvaginal ultrasound segment is anticipated to hold the largest share of the global PCOS diagnostic market during the forecast period.    

On the basis of the type of diagnostic test, the global PCOS diagnostic market is divided into pelvic exam, blood test, transvaginal ultrasound, and others. Among these, the transvaginal ultrasound segment is anticipated to hold the largest share of the global PCOS diagnostic market during the forecast period. Women's responses to medications usually decrease over time, which may be related to the infertility problems these illnesses cause in women. Moreover, this procedure is affordable and straightforward, which is driving the global expansion of the industry.

• The hospitals & clinics segment is anticipated to hold the highest share of the global PCOS diagnostic market during the forecast period.

On the basis of the end user, the global PCOS diagnostic market is divided into hospitals & clinics, fertility clinics, and others. Among these, the hospitals & clinics segment is anticipated to hold the highest share of the global PCOS diagnostic market during the forecast period. The increasing incidence of PCOS and related operations that are performed more commonly in hospital locations. The first option for PCOS diagnosis and treatment is a hospital. Clinicians must first diagnose PCOS patients because there isn't a single test that can accurately diagnose PCOS.

Regional Segment Analysis of the Global PCOS Diagnostic Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global PCOS diagnostic market over the predicted timeframe.

North America is anticipated to hold the largest share of the global PCOS diagnostic market over the predicted timeframe. The growing number of cases of obesity and overweight is raising the prevalence of women suffering from PCOS. The region has well-established healthcare facilities, advanced diagnostic infrastructure, and high cases of PCOS in women. Factors, like raised awareness, availability of healthcare services, and advantageous settlement policies contribute to the growth of the market in the North America region. In addition, the presence of key diagnostic companies and continuous research activities further propel the growth of the market in this region. These factors, expand the PCOS diagnostic market over the predicted timeframe.

Asia-Pacific is anticipated to grow at the fastest rate in the global PCOS diagnostic market over the predicted timeframe. This region presents important growth opportunities in the PCOS diagnostic market. Factors, like the huge population, increasing healthcare funding, and rising awareness regarding women’s health contribute to the expansion of the market in this region.  Nations like India and China have a high load of PCOS, and the market is fueled by the increasing demand for diagnostic tests and advancements in healthcare facilities. These factors drive the growth of the PCOS diagnostic market over the predicted timeframe in this region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global PCOS diagnostic market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Abbott
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories
• Vitrolife
• Ansh Labs
• Beckman Coulter, Inc.
• GE Healthcare
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche Ltd
• Quest Diagnostics
• Siemens Healthineers
• Hologic, Inc.
• Myriad Genetics, Inc.
• Diagnostica Stago Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2023, Proov, a startup that developed a PdG test for use at home that detects progesterone metabolite PdG in urine, has partnered with Quest Diagnostics, a provider of PCOS diagnostic test kits, to make the Proov Confirm PdG home collection kit available for use at questhealth.com.

• In January 2022, a biotechnology company named Celmatix Inc., which specializes in ovarian biology, announced reaching a third milestone in its five-year collaboration with Evotec across many targets. By advancing a PCOS treatment program focused on a distinct therapeutic target identified by Celmatix into hit identification, Evotec and Bayer AG have achieved a noteworthy milestone.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global PCOS diagnostic market based on the below-mentioned segments: 

Global PCOS Diagnostic Market, By Type of Diagnostic Test

• Pelvic Exam
• Blood Test
• Transvaginal Ultrasound
• Others

Global PCOS Diagnostic Market, By End User

• Hospitals & Clinics
• Fertility Clinics
• Others

Global PCOS Diagnostic Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa